. Author manuscript; available in PMC: 2013 Sep 1.

Published in final edited form as: Circ Cardiovasc Imaging. 2012 Jun 28;5(5):596–603. doi: 10.1161/CIRCIMAGING.112.973321

Table 3.

Temporal Changes in Biomarkers During Treatment by Anthracyclines, Taxanes, and Trastuzumab

	Before Treatment	Postanthracyclines (3 Mo)	6 Mo	9 Mo	12 Mo	End of Treatment
UsTnI, pg/mL	1.3 (0.7–6)	23 (10–42)^*	14 (8–28)^*	9 (6–16)^*	6 (3–15)^*	6 (3–11)^*
NT-proBNP, pg/mL	71 (37–139)	75 (34–117)	59 (32–100)	62 (39–109)	61 (32–113)	75 (38–148)
ST2, pg/mL	26 (23–35)	27 (23–42)	26 (21–32)	27 (21–33)	25 (22–32)	25 (22–31)

UsTnI indicates ultrasensitive troponin I; NT-proBNP, N-terminal pro–B-type natriuretic peptide; and ST2, ST2 protein.

The parameters were log-transformed and the analysis was performed using an ANOVA for repeated measurements on 69 patients with complete follow-up.

P<0.0001 vs before treatment.